Aerocrine Soars Most Ever on FDA Approval for Asthma Treatment
Posted on March 4, 2008
Filed Under FDA, News |
By Jakob Lindstroem
March 4 (Bloomberg) — Aerocrine AB, the Swedish developer of airway inflammation detection equipment, surged the most ever in Stockholm trading after gaining approval to sell an asthma product in the U.S.
Aerocrine rose as much as 11.4 kronor, or 84 percent, to 25 kronor, and traded at 24.5 kronor as of 10:28 a.m. That values the Solna, Sweden-based company at 1.13 billion kronor ($183 million). The shares began trading in June.
The U.S. Food and Drug Administration approved the sale of Niox Mino product in the U.S., Aerocrine said in an e-mailed statement.
To contact the reporter on this story: Jakob Lindstroem in Stockholm at jlindstroem@bloomberg.net.
Comments
Leave a Reply
